52 results about "Salmonella typhosa" patented technology

The invention discloses a polypeptide drug for resisting gram-negative bacteria and application, and belongs to the technical field of biological medicine. The MIC of the antibacterial peptide obtained through screening on escherichia coli, salmonella typhimurium, pseudomonas aeruginosa, klebsiella pneumoniae, shigella sonnei and stenotrophomonas maltophilia is 16 [mu] g / mL, 2 [mu] g / mL, 16 [mu] g / mL, 4 [mu] g / mL, 2 [mu] g / mL and 4 [mu] g / mL respectively, and the antibacterial peptide has broad-spectrum antibacterial performance. The hemolytic activity and toxicity of the compound are lower than therapeutic concentration threshold values, and the compound can be used for preparing drugs or medical products for treating multi-drug-resistant bacterium infection.

The invention relates to the technical field of probiotic development and utilization, in particular to a goose source Weissella cibaria F11 and application thereof. The Weissella cibarius F11 is preserved in the China General Microbiological Culture Collection Center on July 11, 2025, and the preservation number is CGMCC NO.35211. The Weissella cibarius F11 has the characteristics of good acid resistance and cholate resistance, and can be used for preparing the acid-resistant and cholate-resistant strain. And the bacillus subtilis has a good inhibition effect on pathogenic bacteria such as escherichia coli, pseudomonas aeruginosa, staphylococcus aureus and salmonella typhimurium, and also has stable acid production capacity and good safety. The Weissella sinus F11 provided by the invention meets the probiotic characteristic standard, the antibiotic resistance spectrum of the Weissella sinus F11 meets the feed probiotic safety standard, the growth of goslings can be remarkably promoted, the death rate and diarrhea occurrence rate of the goslings can be remarkably reduced, and the weissella sinus F11 can be used for preparing feed probiotics. The development potential in the fields of preparation of bacteriostatic and antibacterial drugs, probiotics for poultry feed, feed additives, poultry feed and the like is huge.

This invention discloses a method for detecting *Salmonella typhimurium* based on magnetic covalent organic frameworks and aptamer-modified gold nanoparticles, belonging to the field of food safety technology. The method uses a magnetic covalent organic framework as a capture probe to capture *Salmonella typhimurium* present in the detection system. After incubation, the magnetic covalent organic framework-*Salmonella typhimurium* complex is collected by magnetic separation. Then, aptamer-modified gold nanoparticles are added, and after incubation, the complex formed by the magnetic covalent organic framework-*Salmonella typhimurium* complex and the aptamer-modified gold nanoparticles is collected by magnetic separation. Finally, a TPE-4A / hydrogen peroxide substrate solution is added, and the absorbance and / or fluorescence intensity are measured. Color parameters are extracted using a smartphone. This method is simple to operate, highly sensitive, and highly specific. Three detection modes work together for self-testing, resulting in accurate and reliable results.

This invention belongs to the field of molecular biology detection technology, specifically relating to a primer and probe combination for detecting avian Salmonella based on the RAA-LFD method and its application, particularly to a primer and probe combination for detecting three avian serotypes of Salmonella: Salmonella pullorum, Salmonella enteritidis, and Salmonella typhimurium, based on the RAA-LFD method and its application. This invention designs different types of probes and primers targeting the genes of serotypes SP, SE, and STM of Salmonella. Using the primer and probe combination of this invention, rapid, sensitive, and specific detection of Salmonella serotypes and the three avian Salmonella serotypes SP, SE, and STM can be achieved, greatly shortening the detection cycle of avian salmonellosis and improving the detection efficiency and accuracy of avian salmonellosis.

A novel bacteriophage having bacteriolytic activity against bacteria of the genus Salmonella, such as S. Enteritidis, and a bacteriolytic agent consisting of the same are provided. The bacteriophage and the bacteriolytic agent including the bacteriophage have a wide host range for bacteria of the genus Salmonella. A host-specific bacteriophage and an effective Salmonella bacteriolytic agent consisting of the same are provided. A bacteriophage capable of effectively controlling S. Typhimurium, and in particular, multidrug-resistant S. Typhimurium, and a bacteriolytic agent consisting of the same are also provided. A bacteriophage having a specific genomic DNA sequence; a Salmonella bacteriolytic agent consisting of the bacteriophage; and a composition comprising the same are provided.

The invention discloses an application of bilobalide in preparation of a product for resisting salmonella typhimurium infection. The bilobalide takes salmonella typhimurium QseB protein as a target, has a good interference effect on an AI-2 quorum sensing signal of salmonella typhimurium and has good pharmacological activity, and particularly, the bilobalide has good pharmacological activity under the condition that the growth of salmonella typhimurium is not inhibited. The motility, biofilm formation and infection pathogenicity of salmonella typhimurium are obviously inhibited. The bilobalide does not influence the growth of salmonella typhimurium, directly acts on pathogenic factors, weakens the pathogenicity of bacteria from the source, does not generate selective pressure on salmonella typhimurium, and does not cause the generation of drug-resistant pathogenic bacteria. Therefore, the bilobalide has a good application prospect in the aspect of development of the salmonella typhimurium infection resisting medicine.

The present invention provides compositions and methods of inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live Salmonella typhi vector comprising a heterologous antigen from a pathogen, wherein the heterologous antigen comprises an outer membrane protein, an antigenic fragment thereof or a variant thereof, wherein the antigen is delivered to a mucosal tissue of the subject by an outer membrane vesicle.

The invention relates to the field of biological detection, in particular to a primer probe set, a detection reagent and application of the primer probe set and the detection reagent in detection of virulent pathogenic bacteria. The invention provides a primer probe group. The primer probe group comprises a primer probe group used for amplifying bacillus anthracis, Francisella tularensis, bacillus plague, rhinotrichum-like bacteria, brucella, vibrio cholerae, salmonella typhimurium and staphylococcus aureus, wherein the primer probe group is used for amplifying bacillus anthracis, Francisella tularensis, bacillus plague, rhinotrichum-like bacteria, brucella, vibrio cholerae and salmonella typhimurium. The invention establishes a primer probe combination for rapidly and sensitively detecting various virulent pathogenic bacteria and a kit thereof, aiming at eight virulent pathogenic bacteria such as bacillus anthracis, Francisella tularensis, bacillus plague, rhinotrichum, vibrio cholerae, brucella, salmonella typhimurium and staphylococcus aureus. The kit is stored in a freeze-dried state, adaptive sample lysate can directly expand different types of samples, and the kit has the advantages of being good in specificity, high in sensitivity, short in detection time, good in accuracy, good in stability after redissolution and good in compatibility.

The invention belongs to the technical field of food safety, and relates to application of peanut red skin proanthocyanidin nano-liposome in inhibition of salmonella typhimurium, and the peanut red skin proanthocyanidin nano-liposome causes cell death by causing permeability change of cell membranes and cell walls of salmonella typhimurium. According to the present invention, the inherent limitation of the natural antibacterial substance PSPc is overcome through the efficient delivery system of the nano-liposome, such that the salmonella typhimurium inhibition activity of the nano-liposome can be completely performed and durably maintained, the method is efficient and safe, the application potential in the food preservation aspect is provided, and the value-added utilization of the peanut resource is improved.

The invention relates to the technical field of microorganisms, in particular to Eubacterium mucilaginosus E11405 and application thereof in bacteriostasis and anti-inflammation. The preservation number of the mucus eubacterium is CGMCC (China General Microbiological Culture Collection Center) No.31231. The application comprises inhibition of microorganisms and anti-inflammation. The microorganisms comprise one or more of listeria monocytogenes, staphylococcus aureus, salmonella typhimurium or escherichia coli. The Eubacterium mucilaginosus provided by the invention can relieve various infection symptoms caused by salmonella infection, and shows the potential in preparation of drugs for treating and / or preventing infection of pathogenic bacteria such as salmonella. In addition, the Eubacterium mucilaginosus provided by the invention can also effectively relieve inflammatory bowel diseases and relieve intestinal mucosa injury and colitis symptoms, provides a new strategy for preventing and treating inflammatory bowel diseases, and has potential clinical application prospects.

This invention relates to the field of microbial technology, and particularly to a non-lactolytic streptococcus and its application in the preparation of anti-Salmonella infection agents. This invention provides a non-lactolytic streptococcus, wherein the non-lactolytic streptococcus (… Streptococcus alactolyticus The strain was deposited at the China Center for Type Culture Collection (CCTCC) on March 30, 2026, with accession number CCTCC NO: M 2026565. Pre-gavage administration of the described non-lactose-degrading Streptococcus significantly enhanced the host's resistance to Salmonella typhimurium. Host weight loss was slowed after Salmonella typhimurium infection, and the amount of Salmonella typhimurium in the liver and spleen was suppressed, reducing the host's pathogenic load.

The invention belongs to the technical field of microbiological detection, and discloses an RPA (recombinase polymerase amplification) primer pair, a real-time fluorescent RPA primer group and a kit for detecting salmonella typhimurium. The primer pair for detecting the salmonella typhimurium based on the RPA comprises an upstream primer RPA-F with a sequence as shown in SEQ ID NO: 1 and a downstream primer RPA-R with a sequence as shown in SEQ ID NO: 2, and the primer group for detecting the salmonella typhimurium based on the real-time fluorescence RPA comprises the upstream primer RPA-F, the downstream primer RPA-R and a probe RPA-P with a sequence as shown in SEQ ID NO: 3. The primer group and the primer pair can be used for rapidly detecting salmonella typhimurium, and are high in specificity and sensitivity and low in minimum detection limit.

The present disclosure relates to the technical field of medicine, and in particular to a pharmaceutical composition, preparation method and use thereof. The pharmaceutical composition includes a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient. The first active ingredient is a microbial agent, including one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi. The second active ingredient includes polyinosinic acid, polycytidylic acid, and vitamin. The pharmaceutical composition of the present disclosure pertains to an artificial active immunotherapy for tumors. It can “stimulate” the entire immune system, making the therapy of using bacteria to activate the human immune system to kill cancer cells highly stable and reliable. This composition can significantly save and prolong the lives of cancer patients while exhibiting extremely high safety, minimal toxic side effects, and low production costs.

Provided herein are methods and compositions for detecting Salmonella Typhimurium in a sample.

The application belongs to the technical field of biology, and discloses a preparation method of a Salmonella typhimurium flagellin and Senecavirus antigen fusion protein. The application selects Escherichia coli Rosetta (DE3) as a host, fuses a Salmonella typhimurium flagellin gene and a Senecavirus antigen gene, optimizes codons, and then clones the fusion protein into a pET-28a (+) vector, so that the obtained fusion protein can keep the adjuvant activity of the flagellin, improve the solubility and expression level of VP2, and the yield can reach 40 mg / L, thereby greatly reducing the expression and purification process cost. The fusion protein provided by the application can activate the TLR5 path and activate mouse macrophages, and the production process is simple and low in cost, so that the application has important significance for the research and production of Senecavirus subunit vaccines.

The present invention discloses a strain of poultry-derived Salmonella typhimurium ST0602 and its application. The strain has been preserved, and the preservation unit is: China Center for Type Culture Collection; address: Wuhan University; preservation date: May 30, 2024; preservation number: CCTCC NO.M 20241100. The present invention also provides the application of the Salmonella typhimurium for constructing a poultry attenuated vaccine strain. Salmonella typhimurium ST0602 is sensitive to currently common antibacterial drugs and has good genetic stability, and is suitable for constructing a live attenuated vaccine strain of Salmonella typhimurium.

Provided is use of a combination of three or more of the following microorganisms in the preparation of an anti-tumor combination vaccine: Bordetella pertussis, Salmonella typhi, Salmonella paratyphi A, Salmonella paratyphi B, Staphylococcus aureus, Listeria monocytogenes, Escherichia coli, Proteusbacillus vulgaris, Lactic acid bacteria, Bifidobacterium longum, Bordetella pertussis, Corynebacterium diphtheriae and Clostridium tetani, Clostridium acetobutylicum, Salmonella typhimurium, and Streptococcus pyogenes. The anti-tumor combination vaccine is broad-spectrum, safe and non-toxic, and thus has the prospect of clinical applications.

The invention belongs to the field of biological medicines, and particularly relates to a drug-loaded hybrid membrane system for targeting tumor-associated macrophages as well as a preparation method and application of the drug-loaded hybrid membrane system. The invention discloses a hybrid membrane carrier for targeting tumor-associated macrophages. The hybrid membrane carrier is formed by fusing attenuated salmonella typhimurium ghost and an M2pep peptide modified macrophage membrane. The invention also discloses a drug-loaded hybrid membrane system for targeting tumor-associated macrophages. The drug-loaded hybrid membrane system comprises a hybrid membrane carrier and a drug which is loaded in the hybrid membrane carrier and is used for immunoregulation / tumor resistance. The drug-loaded hybrid membrane system provided by the invention integrates the advantages of active targeting, homologous targeting, macrophage specific targeting, biocompatibility, immune activation efficiency and the like, and develops a new treatment mode for malignant tumors with low immunotherapy effect rate.

The invention relates to the technical field of microorganisms, in particular to bacillus altitudinis MLF-1 and a complex microbial inoculant and application thereof.The bacillus altitudinis strain MLF-1 is obtained by being separated from healthy cattle rectum contents by a research group, and it is detected that the strain has the good beta-1, 4-glucanase producing capacity, and the beta-1, 4-glucanase producing capacity is high; the antibacterial effect is achieved on enterobacter aerogenes, staphylococcus aureus, salmonella typhimurium and escherichia coli; the bacillus altitudinis MLF-1 has good fermentation capacity on the siraitia grosvenorii residues, after the bacillus altitudinis MLF-1 is mixed with the bacillus licheniformis strain JSF-9 and the bacillus safensis strain MLL-5 to prepare the complex microbial inoculant, the nutritional value and the disease resistance of the siraitia grosvenorii residues fermented by the complex microbial inoculant are remarkably improved, 10%-15% of the complex microbial inoculant is added into a basic ration, and the content of the complex microbial inoculant in the siraitia grosvenorii residues fermented by the complex microbial inoculant is reduced. The Jersey cattle feed has the effects of reducing cost and improving efficiency for feeding Jersey cattle.

The present invention discloses the use of 2-aminoquinoline in the preparation of a drug for inhibiting Salmonella typhimurium. The present invention inhibits the expression of QS-related genes and virulence genes and the formation of biofilms by binding 2-aminoquinoline to an LsrB protein, thereby reducing the pathogenicity of Salmonella typhimurium. 2-aminoquinoline can also inhibit the invasion and adhesion capabilities of Salmonella typhimurium to cells. Therefore, 2-aminoquinoline can be used in the preparation of a drug for inhibiting Salmonella typhimurium.

The invention relates to the technical field of poultry immunology, in particular to a universal riemerella anatipestifer monoclonal antibody, a detection kit and application of the universal riemerella anatipestifer monoclonal antibody. Specifically, the invention successfully designs the universal riemerella anatipestifer monoclonal antibody, and the detection kit developed based on the monoclonal antibody can rapidly detect the level of the riemerella anatipestifer serum antibody in a sample, and has high sensitivity and strong specificity. The riemerella anatipestifer strain has no cross reactivity with avian enterococcus faecalis, avian salmonella typhimurium, avian escherichia coli and avian salmonella enteritidis, so that the riemerella anatipestifer strain can be applied to rapid screening, epidemiological monitoring and vaccine immune effect evaluation of riemerella anatipestifer infection, and has a wide application prospect.

Disclosed is a method and a device for determining whether a sample contains ampicillin-resistant (AMP-R) non-typhoid Salmonella (NTS). The method comprises detecting, in the sample, the presence of a combination of certain genes or their gene products, wherein the presence of said combination indicates the sample contains AMP-R NTS.

The present application relates to the field of microbial technology, and particularly relates to a broad-spectrum lytic Salmonella sp. phage, a composition and application thereof. The phage is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC No. 45281. The phage is isolated from a strain of Salmonella sp., and the core advantage is that (1) it has super-broad-spectrum lytic activity, and can efficiently lyse at least 11 important Salmonella serotypes such as Salmonella enteritidis and Salmonella typhimurium; (2) it has excellent physicochemical stability, and can still maintain high activity after being treated at pH 4-11 and 60 DEG C for 1 hour. Based on the above characteristics, the present application further provides a composition containing the phage, and application thereof in preparing products for food surface disinfection and preservation and prevention and treatment of livestock Salmonella infection. The phage of the present application solves the problems of narrow host spectrum, poor stability and single application scene in the prior art.

The invention provides a low-toxicity and high-tumor targeting salmonella typhimurium strain. According to the low-toxicity and high-tumor targeting salmonella typhimurium strain, an msbB gene segment (STM142297) and a hemA gene segment (STM142147) are deleted from the strain; the nucleotide sequence of the msbB gene segment is as shown in SEQ ID No. 1, and the nucleotide sequence of the hemA gene segment is as shown in SEQ ID No. 2; the bacterial strain is classified and named as salmonella typhimurium, and is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms, the preservation number is CGMCC No.34793, and the preservation time is June 9, 2025. The obtained strain is low in toxicity, low in damage to hosts, high in tumor targeting performance and suitable for being used as a tumor treatment carrier.

The invention discloses a group of antibacterial polypeptides aiming at gram-negative bacteria, and belongs to the technical field of biological medicines. According to the invention, a group of antibacterial peptides is obtained through screening, and the antibacterial peptides have good broad-spectrum antibacterial performance on escherichia coli, salmonella typhimurium, pseudomonas aeruginosa, klebsiella pneumoniae, shigella sonnei and stenotrophomonas maltophilia. Wherein the hemolytic activity and toxicity of the antibacterial peptides 11A-1, 11A-4 and 11A-5 are lower than therapeutic concentration threshold values, and the antibacterial peptides 11A-1, 11A-4 and 11A-5 can be used for preparing drugs or medical products for treating multi-drug-resistant bacterial infection.

The present application relates to the field of microbial technology, and particularly relates to a bacterium El1405 and application thereof in bacteriostasis and anti-inflammation. The bacterium has a preservation number of CGMCC No.31231. The application includes bacteriostasis and anti-inflammation, and the microorganism includes one or more of Listeria monocytogenes, Staphylococcus aureus, Salmonella typhimurium or Escherichia coli. The bacterium can relieve various infection symptoms caused by Salmonella infection, and shows potential in preparation of a drug for treatment and / or prevention of infection of pathogenic bacteria such as Salmonella. The bacterium can also effectively relieve inflammatory bowel disease, reduce intestinal mucosal damage and colon inflammation symptoms, and provide a new strategy for prevention and treatment of inflammatory bowel disease, and has potential clinical application prospect.

The application belongs to the technical field of biology, and discloses a Salmonella typhimurium flagellin derivative and Senecavirus antigen fusion protein and application thereof. The Salmonella typhimurium flagellin derivative gene and the Senecavirus antigen gene are fused, and after codon optimization, the fusion protein is cloned into a pET-28a(+) vector, and the fusion protein is expressed by using an Escherichia coli system. In-vivo experiment verification shows that the fusion protein has good biological activity, can activate TLR5 ligand activity, and promote macrophage activation, and lays a foundation for development of a Senecavirus subunit vaccine.

The invention discloses identification of a salmonella typhimurium virulence gene Ict and preparation and application of an attenuated vaccine candidate strain of the salmonella typhimurium virulence gene Ict. According to the invention, a virulent salmonella typhimurium SL1344 strain is selected as a parent strain, and a key virulence gene Ict for degrading and metabolizing itaconic acid in the virulent salmonella typhimurium SL1344 strain is knocked out to construct a salmonella typhimurium SL1344 attenuated vaccine candidate strain. A mouse animal toxicity experiment, an immune protection experiment, a safety experiment and the like prove that the vaccine candidate strain SL1344-delta Ict deletion strain not only has obviously reduced pathogenicity to animals, but also provides good immunogenicity and immune protection. The attenuated salmonella typhimurium strain disclosed by the invention can be used for attenuating the virulence salmonella typhimurium strain, can be widely applied to prevention and control of salmonella, and lays a foundation for developing attenuated live vaccines and live vector vaccines of salmonella.

Disclosed are engineered outer membrane proteins (OMPs) that comprise one or more extracellular loops from the Salmonella enterica serovar Typhimurium protein PagC or a functional portion thereof. Methods of expressing the engineered outer membrane proteins in a cell, such as a Gram-negative bacteria, to increase the production of outer membrane vesicles are also provided.

The invention discloses a method for detecting salmonella typhimurium based on strand displacement reaction and CRISPR / Cas12a in combination with a colorimetric sensor and a dairy product detection method, and belongs to the technical field of food safety rapid detection. The invention provides a method for detecting salmonella typhimurium based on strand displacement reaction and CRISPR (clustered regularly interspaced short palindromic repeats) / Cas12a combined with a colorimetric sensor in order to solve the problems of low sensitivity and inaccurate result of detection of salmonella typhimurium in dairy products by a traditional method in the prior art. According to the method, DNA-Ag / Pt NCs is used as a signal molecule to construct the aptamer colorimetric sensor for detecting salmonella typhimurium; the colorimetric sensor has relatively high sensitivity and specificity, and can quickly and conveniently realize on-site detection of salmonella typhimurium.